DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Gallbladder Adenocarcinoma — screening already-approved drugs against its 50-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGallbladder Adenocarcinoma maps to a 50-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gallbladder adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tripartite motif containing 24 (TRIM24) — TRIM24 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet benzyloxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4YBM · 1.46 Å · ligand N-{6-[3-(benzyloxy)phenoxy]-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl}-3,4-dimethoxybenzenesulfonamide (4BJ). Experimental structure, not a prediction.
What the evidence adds up to
Gallbladder adenocarcinoma remains a disease where surgery is the only potentially curative option, and this is achievable in a minority of patients. A 2020 proteomics study notes that gallbladder carcinoma is rare and understudied, that radical surgery is the only potentially curative treatment, and that due to late diagnosis few patients are eligible; for unresectable disease, 2-year survival is less than 10%. A 1989 clinical study of 30 operated patients reported an average survival of 15.6 months (range 1 to 72 months) in resectable cases versus 3.9 months (range 8 days to 14 months) in unresectable cases, with four long-term survivors of 3 years or more all having curatively resected papillary adenocarcinomas. A 1988 review states that gallbladder carcinoma has a 5-year survival rate of less than 5%.
Adjuvant chemoradiation has shown benefit in some reports for squamous variants, but no therapy is defined for unresectable gallbladder cancer, including adenocarcinoma. Squamous cell carcinoma accounts for up to 3% of gallbladder malignancies, presents at advanced stage, is often unresectable, and carries a worse prognosis than adenocarcinoma. A 2021 review summarises that newer modalities such as regional therapy and molecularly directed therapy have led to improved outcomes in advanced disease, while a 2023 review states that chemotherapy, radiotherapy, targeted therapy and immunotherapy may improve survival in some patients, but that curing the disease remains difficult. A 2020 case report of an early, well-differentiated squamous cell carcinoma that was completely resected planned adjuvant chemotherapy postoperatively.
The evidence base is thin and largely retrospective, with no randomised data on systemic therapy for gallbladder adenocarcinoma specifically. What is missing is prospective trial data that stratifies patients by molecular profile and resectability, and adequate funding for a disease that remains understudied relative to its lethality.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
World Journal of Gastrointestinal Oncology · 2021 · 74 citations · open access
Gallbladder cancer: Historical treatment and new management options
AbstractGallbladder cancer is a rare, aggressive malignancy that has a poor overall prognosis. Effective treatment consists of early detection and surgical treatment. With the wide spread treatment of gallbladder disease with minimally invasive techniques, the rate of incidental gallbladder cancer has seen an equitable rise along with stage migration towards earlier disease. Although the treatment remains mostly surgical, newer modalities such as regional therapy as well as directed therapy based on molecular medicine has led to improved outcomes in patients with advanced disease. We aim to summarize the management of gallbladder cancer along with the newer developments in this formidable disease process.
Translational Gastroenterology and Hepatology · 2016 · 12 citations · open access
Squamous cell carcinoma of the gallbladder
AbstractGallbladder cancer is the most common malignant tumor of the biliary tract. The majority of cases are adenocarcinoma (AC). Pure squamous cell carcinoma (SCC) of gallbladder accounts only 3% of the malignant neoplasm of this organ. Many patients are at advanced stage when diagnosed and have bad therapeutic efficacy. At present, radical surgery is the only chance to gain long-term survival for patients with early-stage gallbladder cancers. Recent reports have shown a benefit of adjuvant chemoradiation in this type of tumor. At present, no therapy is defined for unresectable cancer of the gallbladder, especially for SCC.
International Surgery Journal · 2020 · 2 citations · open access
Squamous cell carcinoma of gallbladder: a rare entity
AbstractAdenocarcinoma is the most common variant of gallbladder carcinoma. Adenosquamous carcinoma and pure squamous cell carcinoma are rare variants accounting for only up to 3% of the tumors. Pure squamous cell carcinoma of the gallbladder is reported and its incidence is less than 1%. Usually they present at advanced stage and many of the times these are unresectable. Hence survival in patients with squamous cell carcinoma is less than adenocarcinoma, and carries a bad prognosis. We report a rare case of squamous cell carcinoma gallbladder, which was well differentiated, diagnosed early and resected completely. Postoperatively patient is planned for adjuvant chemotherapy.
AbstractGallbladder carcinoma (GBC) is a rare and understudied cancer entity. Radical surgery is the only potentially curative treatment option but due to late diagnosis few patients are eligible and 2-year survival rates of unresectable GBC is less than 10%. Therefore, the development of new treatment options, including targeted therapy for GBC is required to improve patient outcome.
The journal of the Japanese Practical Surgeon Society · 1989 · 0 citations · open access
THE CLINICAL STUDY OF SURGICAL PATIENTS OF THE GALLBLADDER CANCER
AbstractFrom 1979 to 1987, 30 Patients with cacer of the gallbladder were operated. The average age was 66 with a range from 50 to 83 years. The ratio of men-to-women was 1:33. Chief complaints included abdominal pain and jaundice. CT and US were the most effective diagnostic tools for gallbladder cancer, and 19 cancers could be diagnosed preoperatively. Of the 19 patients, 17 were successfully operated, and only 6 of which revealed cures. The averaged survival period was 15.6 months with a range from one to 72 months in resectable cases, while 3.9 months with a range from 8 days to 14 months in unresectable cases. Four long survival patients of 3 years or over have curatively resected papillary adenocarcinomas.
DOAJ (DOAJ: Directory of Open Access Journals) · 2023 · 0 citations · open access
Clinical study on comprehensive treatment of gallbladder cancer
AbstractEarly detection of gallbladder cancer is difficult with poor prognosis in late stage. Although radical surgical treatment is the main method to cure gallbladder cancer at present, only less patients have radical surgery clinically. Chemotherapy, radiotherapy, targeted therapy and immunotherapy may improve the survival of some patients with gallbladder cancer. However, how to cure gallbladder cancer is still difficult clinic. In this paper, the review of literatures at home and abroad on surgical treatment, chemotherapy, radiotherapy, targeted therapy, and immunotherapy for gallbladder cancer was done.
Boletín del Círculo de Empresarios · 1988 · 0 citations
El mercado monetario y de renta fija en España: pasos a dar para una homologación con la "mejor" práctica internacional al respecto
AbstractThe exact pathogenesis of gallbladder adenomyomatosis is still lacking and some controversies over its diagnosis and treatment exist. Originally recognized as a precancerous lesion, adenomyomatosis is currently recognized by recent studies as a benign alteration of the gallbladder that is often associated with cholecystitis and cholecystolithiasis. Gallbladder carcinoma is an extremely malignant disease with a 5-year survival rate of less than 5%. Therefore, it is important to diagnose, differentiate, and confirm the relationship between adenomyomatosis and early-stage gallbladder carcinoma. However, the early clinical symptoms of adenomyomatosis are extremely similar to those of gallbladder stones and cholecystitis, increasing the difficulty to identify and treat this disease. This article summarizes the research progress on gallbladder adenomyomatosis, aiming to improve the understanding of the pathogenesis of adenomyomatosis and further provide insight for its clinical diagnosis and treatment.
AbstractPatients with adenosquamous/squamous cell carcinoma of the gallbladder were generally similar to those with adenocarcinoma in clinical characteristics, but had a tendency for liver infiltration. Although the two histopathologic subtypes of the gallbladder carcinoma had similar poor outcomes, better survival could be obtained by performing curative resection for these patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
